Beatriz Sánchez‐Solana

Supplementary Table S1 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

Summary of molecular alterations in Cohort 1 of MAGNITUDE

Data from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

Abstract On August 11, 2023, the FDA approved the fixed-dose combination of niraparib and abiraterone acetate (AA), with prednisone (AAP), for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer, as determined by an FDA-approved …

Supplementary Table S3 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

Summary of exposure and safety data for safety population (treated patients with BRCAm) of MAGNITUDE

Supplementary Table S2 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

Exploratory efficacy results by type of BRCA mutation in MAGNITUDE

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

On August 11, 2023, the FDA approved the fixed-dose combination of niraparib and abiraterone acetate (AA), with prednisone (AAP), for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer, as determined by an FDA-approved test. …

us (code pays fourni par la source)

cProSite: A web based interactive platform for online proteomics, phosphoproteomics, and genomics data analysis

Dunrui Wang, Xiaolan Qian, Yi‐Chieh Nancy Du, Beatriz Sánchez‐Solana et autres

Abstract We developed cProSite, a website that provides online genomics, proteomics, and phosphoproteomics analysis for the data of The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). This tool focuses on comparisons and correlations between different proteins and mRNAs of tumors …

us (code pays fourni par la source)

Data from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

Abstract In advanced cancer, the RHOA GTPase is often active together with reduced expression of genes encoding Rho-specific GTPase-accelerating proteins (Rho-GAP), which negatively regulate RHOA and related GTPases. Here we used the The Cancer Genome Atlas dataset to examine 12 tumor types …

Data from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

Abstract In advanced cancer, the RHOA GTPase is often active together with reduced expression of genes encoding Rho-specific GTPase-accelerating proteins (Rho-GAP), which negatively regulate RHOA and related GTPases. Here we used the The Cancer Genome Atlas dataset to examine 12 tumor types …

Figure S6 from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

DLC1 Rho-GAP mutants reduce Rho-GAP activity

Table S2 from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

Summary for missense, nonsense, and frame-shift mutations of various tumor types

Table S4 from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

Experimentally analyzed DLC1 mutants

Table S1 from Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sánchez‐Solana, Brajendra K. Tripathi et autres

RT-PCR primers for mutagenesis